- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.10. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.10. | Prenetics Global Limited: IM8 Named Official Nutrition Partner of the NBA in Australia and Southeast Asia | 2 | GlobeNewswire (USA) | ||
| PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
| 12.10. | Lucid Capital Markets initiates Prenetics stock with buy rating | 1 | Investing.com | ||
| 12.10. | Lucid Capital Markets startet Coverage für Prenetics mit Kaufempfehlung | 1 | Investing.com Deutsch | ||
| 22.09. | Prenetics Global Ltd - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 21.09. | Prenetics Global Q2 2026 Earnings Call: Complete Transcript | 1 | Benzinga.com | ||
| 08.09. | StoneX reiterates Buy on Prenetics stock, keeps $40 target | 1 | Investing.com | ||
| 08.09. | Prenetics Global Ltd - F-1/A, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 27.08. | B.Riley initiates Prenetics stock coverage with buy rating on IM8 growth | 4 | Investing.com | ||
| 27.08. | B.Riley stuft Prenetics Aktie mit "Buy" ein - Wachstum durch IM8 im Fokus | 1 | Investing.com Deutsch | ||
| 26.08. | Prenetics Global CEO and CFO purchase $1M of shares in open market | 2 | Seeking Alpha | ||
| 26.08. | Prenetics Global Limited: Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results | 2 | GlobeNewswire (USA) | ||
| 26.08. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 21.08. | Prenetics Global Ltd - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 20.08. | Prenetics Global Limited: Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership | 1 | GlobeNewswire (USA) | ||
| 18.08. | Prenetics Q2 2026 slides: cash flow turns positive, $1B deal fuels growth | 10 | Investing.com | ||
| 18.08. | Prenetics Global GAAP EPS of -$0.53 beats by $0.01, revenue of $46.5M misses by $2.68M | 2 | Seeking Alpha | ||
| 18.08. | Prenetics Global Limited: Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million | 836 | GlobeNewswire (Europe) | Total revenue of $46.5 million, up ~288% YoY (~3.9x); within the Company's guidance of $46-48 millionIM8 revenue of $45.0 million, up ~359% YoY (~4.6x); within the Company's guidance of $44-46 million... ► Artikel lesen | |
| 17.08. | Prenetics Global Q2 2026 Earnings Preview | 5 | Seeking Alpha | ||
| 17.08. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS | 739,00 | +0,37 % | Regeneron Extends BARDA Agreement For Additional Ebola Treatment Supply | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced an extension of its agreement with the U.S. Biomedical Advanced Research and Development Authorities (BARDA) to provide additional... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,850 | +0,21 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update | .release-content span.prnews_span{font-size:8pt;font-family:"Arial";color:black}.release-content a.prnews_a{color:blue}.release-content li.prnews_li{font-size:8pt;font-family:"Arial";color:black}.release-content... ► Artikel lesen | |
| GUARDANT HEALTH | 165,08 | +0,28 % | BTIG raises Guardant Health stock price target on growth outlook | ||
| CANSINO BIOLOGICS | 3,000 | +1,35 % | CanSino Biologics Inc: CanSinoBIO Reports Growth in First Nine Months: Commercialization Accelerates Across Multiple Products as Platform Innovation Opens New Avenues for Growth | HONG KONG, Oct 27, 2026 - (ACN Newswire) - On October 27, 2026, CanSino Biologics Inc. (HKEX: 06185; SSE: 688185) released its third-quarter financial report for 2026. For the nine months ended September... ► Artikel lesen | |
| SINO BIOPHARM | 0,543 | -0,89 % | SBP GROUP Two Hepatitis B New Drugs Included in Breakthrough Therapy Designation Program | ||
| INNOVENT BIOLOGICS | 9,156 | -0,61 % | INNOVENT BIO (01801): INSIDE INFORMATION ANNOUNCEMENT - PRODUCT REVENUE IN THE THIRD QUARTER OF 2026 | ||
| BIO-TECHNE | 65,12 | -0,12 % | BIO-TECHNE Corp - 10-K/A, Annual Report | ||
| GENSCRIPT BIOTECH | 4,320 | +0,93 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 13.10.2026 | Das Instrument DTT ZAE000017745 DATATEC LTD RC-,01 EQUITY wird cum Kapitalmassnahme gehandelt am 13.10.2026 und ex Kapitalmassnahme am 14.10.2026 The instrument DTT ZAE000017745 DATATEC LTD RC-,01 EQUITY... ► Artikel lesen | |
| QUANTUM-SI | 1,750 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus | BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics company redefining protein analysis through single-molecule... ► Artikel lesen | |
| AKESO | 9,630 | +1,56 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| SCILEX | 1,810 | -3,21 % | Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026 | PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and... ► Artikel lesen | |
| ORIGIN AGRITECH | 0,695 | 0,00 % | Origin Agritech Ltd.: Origin Agritech Strengthens Liquidity by Selling Its Xinjiang Seed Subsidiary and Leasing Back the Production Base | The sale brings approximately US$15.0 million to support working capital, R&D, new corn varieties, and market expansion, while the five-year lease-back maintains supply stability BEIJING, Oct. 01... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 38,570 | -0,05 % | 1 von 31 Kindern: Warum NeuroTheras Autismus-Studie an Roche, Harmony Biosciences und Jazz Pharmaceuticals gemessen wird | ||
| NIKI BIOSOLUTIONS | 1,810 | -1,09 % | Niki BioSolutions receives New York approval for expanded APOE test | ||
| QIAGEN | 45,050 | -0,11 % | EQT lässt für Qiagen 9,6 Milliarden Euro springen | Der schwedische Private-Equity-Investor EQT übernimmt den europäische Molekulardiagnostik-Spezialisten Qiagen. Mit 9,6 Mrd. Euro ist die Transaktion eine der größten Übernahmen im europäischen Gesundheitssektor... ► Artikel lesen |
PRENETICS GLOBAL LIMITED gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,050 (-0,26 %) liegt der Kurs bei 18,930 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.